NORTH BILLERICA, Mass.--(BUSINESS WIRE)-- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a global ...

NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Medical Imaging, Inc. (“Lantheus”) today announced U.S. Food and Drug Administration (FDA) approval of an important label update for DEFINITY ® Vial ...

In most cases, the targeted microbubble contrast agents (MCAs) are fitted with a high-affinity targeting ligand. After the MCAs are adhered to the target, they begin to improve the acoustic signal ...

NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a global ...

London: The ultrasound contrast agents (microbubbles) market is driven by their role in enhancing diagnostic capabilities and revolutionising treatment methods. The demand for microbubbles will stem ...